You are here: Industry Insights > Orion

News List

Evofem Biosciences, Orion Biotechnology Enter OB-002 Alliance contractpharma
December 20, 2021
To evaluate Orion's CCR5 antagonist, OB-002, in Evofem's Phexxi vaginal gel with the goal of developing a Multipurpose Prevention Technology for HIV.
Orion Biotechnology Secures $11.5M Series A Financing firstwordpharma
June 24, 2021
Orion Biotechnology Canada Ltd., a clinical-stage biotechnology company, today announced that it has raised $11.5M USD in a Series A financing.
Orion Biotechnology Project Awarded Grant to Advance Drug Discovery americanpharmaceuticalreview
January 21, 2021
Orion Biotechnology announced its drug discovery project was awarded funding of CHF 0.9M from Innosuisse, the Swiss Innovation Agency.
Novartis’ cholesterol med Leqvio wins EU approval pharmatimes
December 15, 2020
Swiss pharma company Novartis’ cholesterol-lowering drug Leqvio (inclisiran) has been granted approval from the European Commission (EC) for the treatment of primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
Orion and Bayer secure FDA approval for prostate cancer drug pharmaceutical-technology
August 01, 2019
Orion and Bayer have obtained the US Food and Drug Administration (FDA) approval for Nubeqa (darolutamide) to treat non-metastatic castration-resistant prostate cancer (nmCRPC).
Orion takes repurposed heart failure drug into phase 3 for ALS fiercebiotech
July 09, 2018
Finnish drugmaker Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial.